Welcome to CDC Stacks | CHROMIUM EFFECTS ON GLUCOSE TOLERANCE AND INSULIN SESITIVITY IN PERSONS AT RISK FOR DIABETES MELLITUS - 33212 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
CHROMIUM EFFECTS ON GLUCOSE TOLERANCE AND INSULIN SESITIVITY IN PERSONS AT RISK FOR DIABETES MELLITUS
Filetype[PDF - 334.89 KB]


Details:
  • Pubmed ID:
    20634174
  • Pubmed Central ID:
    PMC3118091
  • Funding:
    F32 AT002667/AT/NCCIH NIH HHS/United States
    F32 AT002667/AT/NCCIH NIH HHS/United States
    F32 AT002667-03/AT/NCCIH NIH HHS/United States
    L30 AT004887/AT/NCCIH NIH HHS/United States
    L30 AT004887-02/AT/NCCIH NIH HHS/United States
    R01 ES016893/ES/NIEHS NIH HHS/United States
    R21 AT001332/AT/NCCIH NIH HHS/United States
    R21 AT001332-01A1/AT/NCCIH NIH HHS/United States
    R21 AT001332-02/AT/NCCIH NIH HHS/United States
    R21 AT001332-02S1/AT/NCCIH NIH HHS/United States
    R21 AT1332/AT/NCCIH NIH HHS/United States
    U48 DP000053/DP/NCCDPHP CDC HHS/United States
    UL1 RR024139/RR/NCRR NIH HHS/United States
  • Document Type:
  • Collection(s):
  • Description:
    Objective

    To investigate the effects of daily chromium picolinate supplementation on serum measures of glucose tolerance and insulin sensitivity in patients at high risk for type 2 diabetes mellitus.

    Methods

    We conducted a randomized, double-blind, placebo-controlled, modified cross-over clinical trial with 6-month sequences of intervention and placebo followed by a 6-month postintervention assessment. Adult patients with impaired fasting glucose, impaired glucose tolerance, or metabolic syndrome were enrolled. Participants received 6-month sequences of chromium picolinate or placebo at 1 of 2 dosages (500 or 1000 mcg daily). Primary outcome measures were change in fasting plasma glucose, 2-hour plasma glucose during oral glucose tolerance testing, fasting and 2-hour insulin, and homeostasis model assessment of insulin resistance (HOMA-IR). Secondary outcomes included anthropometric measures, blood pressure, endothelial function, hemoglobin A1c, lipids, and urinary microalbumin.

    Results

    Fifty-nine participants were enrolled. No changes were seen in glucose level, insulin level, or HOMA-IR (all, P>.05) after 6 months of chromium at either dosage level (500 mcg or 1000 mcg daily) when compared with placebo. None of the secondary outcomes improved with either chromium dosage compared with placebo (P>.05).

    Conclusions

    Chromium supplementation does not appear to ameliorate insulin resistance or impaired glucose metabolism in patients at risk for type 2 diabetes and thus is unlikely to attenuate diabetes risk.